Dechra Pharmaceuticals PLC Director/PDMR Shareholding (1366Z)
12 Septiembre 2022 - 6:18AM
UK Regulatory
TIDMDPH
RNS Number : 1366Z
Dechra Pharmaceuticals PLC
12 September 2022
12 September 2022
Dechra(R) Pharmaceuticals PLC
(Dechra or the Company)
LEI: 213800J4UVB5OWG8VX82
Notification and public disclosure of transactions by
persons discharging managerial responsibilities (PDMRs)
The Company announces that on 9 September 2022 the following
Directors were granted awards over Ordinary Shares of 1 pence each
in the Company under the Dechra 2017 Long Term Incentive Plan:
Name of individual Director Type of award Number of shares
subject to award
LTIP Award -
Ian Page Director nil cost option 38,261
---------- ------------------ ------------------
LTIP Award -
Paul Sandland* Director nil cost option 18,990
---------- ------------------ ------------------
LTIP Award -
conditional
Tony Griffin Director award 10,429
---------- ------------------ ------------------
* Paul Sandland has also been granted a tax qualifying option
over 431 shares at an exercise price of GBP31.99 as part of his
LTIP award. This tax qualifying option is linked to the nil cost
option such that, at the time of exercise, to the extent that there
is a gain in the tax qualifying option, the nil cost option will be
forfeited to the value of that gain.
The vesting of all the above awards is subject to the
achievement of performance targets. In respect of these grants the
performance conditions will be determined by reference to the
Company's Earnings per Share (EPS) and its Total Shareholder Return
(TSR) relative to constituent companies of the FTSE 250 index
(excluding investment trusts) over a three year performance period.
Both the EPS and TSR elements will be subject to an additional
Return on Capital Employed (ROCE) performance condition. If the
ROCE performance condition is not met, then the LTIP Awards will
lapse in full.
The Notification of Dealing Forms set out below are provided in
accordance with the requirements of the Market Abuse
Regulation.
Notification of Dealing Forms
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Ian Page
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Director
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- -----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of awards over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) Nil cost option
Price Volume
Nil cost award 38,261
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2022-09-09
----------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Paul Sandland
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Director
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- -----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of an award over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) Nil cost option
Price Volume
Nil cost award 18,990
-------
Tax qualifying option
Price Volume
GBP31.99 (per Ordinary
Share exercise price) 431
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume
Awards granted over 19,421 Ordinary
Shares in total
* Price
N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2022-09-09
----------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- -----------------------------------------
1. Details of the Person Discharging Managerial Responsibility
("PDMR")/person closely associated with them ("PCA")
a) Name Tony Griffin
----------------------------- -----------------------------------------
2. Reason for the notification
------------------------------------------------------------------------
a) Position/status Director
----------------------------- -----------------------------------------
b) Initial notification/ Initial Notification
amendment
----------------------------- -----------------------------------------
3. Details of the Issuer
------------------------------------------------------------------------
a) Name Dechra Pharmaceuticals PLC
----------------------------- -----------------------------------------
b) LEI code 213800J4UVB5OWG8VX82
----------------------------- -----------------------------------------
4. Details of the transaction(s): section to be repeated
for (i) each type of instrument; (ii) each type of
transaction; (iii) each date; and (iv) each place
where transactions have been conducted
------------------------------------------------------------------------
a) Description of Ordinary Shares of 1 pence each
the financial
instrument ISIN: GB0009633180
Identification
code
----------------------------- -----------------------------------------
b) Nature of the Grant of an award over Ordinary Shares
transaction under the Company's Long Term Incentive
Plan
----------------------------- -----------------------------------------
c) Price(s) and volumes(s) Conditional award
Price Volume
Nil cost award 10,429
-------
----------------------------- -----------------------------------------
d) Aggregated information
* Aggregate volume
N/A
* Price N/A
----------------------------- -----------------------------------------
e) Date of the transaction 2022-09-09
----------------------------- -----------------------------------------
f) Place of the transaction Outside a trading venue
----------------------------- -----------------------------------------
For further information, please contact:
Melanie Hall, Company Secretary
Telephone number: 01606 814730
About Dechra
Dechra is a global specialist veterinary pharmaceuticals and
related products business. Our expertise is in the development,
manufacture, and sales and marketing of high quality products
exclusively for veterinarians worldwide. Dechra's business is
unique as the majority of its products are used to treat medical
conditions for which there is no other effective solution or have a
clinical or dosing advantage over competitor products. For more
information please visit: www.dechra.com
Trademarks
Dechra and the Dechra "D" logo are registered trademarks of
Dechra Pharm aceuticals PLC.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
DSHBBGDCRBBDGDD
(END) Dow Jones Newswires
September 12, 2022 07:18 ET (11:18 GMT)
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Mar 2024 a Abr 2024
Dechra Pharmaceuticals (LSE:DPH)
Gráfica de Acción Histórica
De Abr 2023 a Abr 2024
